Please use this identifier to cite or link to this item:
Title: Meloxicam synergistically enhances the in vitro effects of sunitinib malate on bladder-cancer cells
Authors: Arantes Rodrigues,R
Pinto Leite,R
Lio Gonçalves
Issue Date: 2013
Abstract: To evaluate the in vitro effects of sunitinib malate and meloxicam in isolation, and to analyse the ability of meloxicam to enhance the cytotoxicity of sunitinib malate in three human bladder-cancer call lines. Cell lines were treated with sunitinib malate and meloxicam, either in isolation or combined. Leishman staining, MTT method, comet assay, MDC staining and M30 CytoDEATH antibody were performed. The Chou and Talalay method was applied. Sunitinib malate and meloxicam supressed cell proliferation in bladder-cancer cells in isolation, in a concentration-dependent manner. Treatment of bladder-cancer cells with a combination of sunitinib malate and meloxicam showed a synergistic effect. When exploring the mechanism of this combination by means of comet assay, there is the suggestion that meloxicam increases sunitinib malate cytotoxicity through DNA damage. Autophagic and apoptotic studies show a greater incidence of autophagic vacuoles and early apoptotic cells when the combined treatment was put into use. In isolation, sunitinib malate and meloxicam demonstrated anti-tumor effects in our study. Furthermore, simultaneous exposure of cells to sunitinib malate and meloxicam provided a combinatorial beneficial effect. This hints at the possibility of a new combined therapeutic regimen, which could lead to improvements in the treatment of patients with bladder cancer.
metadata.dc.type: article
Appears in Collections:Non INESC TEC publications - Articles in International Journals

Files in This Item:
File Description SizeFormat 
  Restricted Access
2.47 MBAdobe PDFThumbnail
View/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.